Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Marker Therapeutics, Inc. Director's Dealing 2009

Oct 26, 2009

35150_dirs_2009-10-26_0b5480c8-a1d5-49a9-9eaa-fb883faf8899.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2009-02-04

Reporting Person: CORIN DENIS (Director, President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2009-06-29 Common stock J 1925750 $0.1 Acquired 1933750 Direct
2009-06-29 Common stock J 295300 $0.1 Acquired 295300 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2009-02-04 Purchase Warrants $2 A 14458 Acquired 2011-02-04 Common stock (14458) Direct
2009-10-14 Stock Options $0.97 A 1100000 Acquired 2019-10-14 Common stock (1100000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Purchase Warrants $2.5 2010-08-15 Common stock (5000) 5000 Direct
Purchase Warrants $0.1 2009-08-15 Common stock (15000) 20000 Direct
Purchase warrants $0.1 2010-11-15 Common stock (20000) 40000 Direct
Purchase warrants $2.5 2010-08-15 Common stock (2400) 2400 Indirect
Stock Options $0.97 2017-06-08 Common stock (80000) 80000 Direct
Stock Options $0.97 2017-06-08 Common stock (20000) 20000 Indirect

Footnotes

F1: These shares were issued as part of a larger transaction in which the Issuer converted outstanding debt of approximately $4,137,000 into approximately 3,333,800 shares of common stock.

F2: These stock options were repriced on October 14, 2009 from $2.50 to $0.97.